177lu-dota-sna040
Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)
SmartNuclide BiopharmaradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
112 Active assets in the Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan AstraZeneca | Phase 3 | BBB |
Cyclophosphamide Beijing Biotech | Phase 3 | BB |
Pembrolizumab Eikon Therapeutics | Phase 3 | BB |
FLUOROURACILUM Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Eloxatin Alliance for Clinical Trials in Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
177lu-dota-sna040 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →